Table 3.
Histone deacetylase inhibitors (HDACi) in combination with other anticancer agents: phase I/II/III clinical trials.
| HDACi | Combination(s) | Cancer(s) | Phase I/II/III clinical trial |
|---|---|---|---|
| Vorinostat (SAHA) | Olaprarib, gemcitabine, busulfan and melphalan | Hodgkin’s or non-Hodgkin’s lymphoma | I/II |
| Radiotherapy | Gastrointestinal cancer | I | |
| Radiotherapy | Non-small cell lung (NSCLC) | I | |
| Radiotherapy and capeceitabine | Non-metastatic pancreatic | I | |
| Doxorubicin | Advanced solid tumors | I | |
| Pegylated liposomal doxorubicin | Relapsed or refractory lymphoma | I/II | |
| Doxorubicin hydrochloride liposome and bortezomib | Relapsed or refractory multiple myeloma | I | |
| Carboplatin and paclitaxel | Advanced solid malignancies | I | |
| Carboplatin, paclitaxel, placebo | NSCLC | II | |
| Carboplatin or paclitaxel | Advanced solid tumors | I | |
| Bortezomib | NSCLC | II | |
| Carfilzomib | Relapsed/refractort B-cell lymphoma | I | |
| Tamoxifen | Breast | II | |
| Tamoxifen and pembrolizumab | Breast | II | |
| Bacalutamide and radical prostatectomy | Prostate | II | |
| Gefitinib | Relapsed or refractory NSCLC | I/II | |
| Sorafenib | Advanced liver | I | |
| Pembrolizumab | Renal or urothelial cell carcinoma | I | |
| Pembrolizumab | NSCLC | I/II | |
| Pembrolizumab | Breast | II | |
| Rituximab | Lymphoma/leukemia | II | |
| Valproic acid | Temozolomide and radiation | Brain | II |
| Epirubicin | Advanced solid tumors | I | |
| Epirubicin/FEC | Breast | I/II | |
| Decitabine | Leukemia | I/II | |
| Panobinostat (LBH589) | Radiotherapy | Prostate, esophageal, and head and neck | I |
| Carfilzomib | Relapsed/refractory multiple myeloma | I/II | |
| Bortezomib | Relapsed/refractory T-cell lymphoma (TCL) or NK/TCL | II | |
| Bicalutamide | Prostate | I/II | |
| Sorafenib | Hepatocellular carcinoma, kidney and soft tissue carcinoma | I | |
| Everolimus | Multiple myeloma, non-Hodgkin or Hodgkin lymphoma | I/II | |
| Ipilimumab | Melanoma | I | |
| Romidepsin (FK288) | Carfilzomib | Relapsed/refractory PTCL | I/II |
| Gemcitabine, dexamethasone and cisplatin | PTCL and diffuse large B-cell lymphoma | I | |
| 5-azacitidine | Relapsed/refractory lymphoid maligancies | I/II | |
| Belinostat (PXD101) | Doxorubicin | Soft tissue sacrcoma | I/II |
| Carboplatin and/or paclitaxel | Solid tumors | I | |
| Entinostat (MS275-SNDX-275) | Sorafenib tosylate | Solid tumors or acute myeloid leukemia (AML) | I |
| Exemestane | Breast | I | |
| Pembrolizumab | Advanced solid tumors | I | |
| Pembrolizumab | Metastatic melanoma of the eye | II | |
| Nivolumab | NSCLC | II | |
| Avelumab | Epithelial ovarian | I/II | |
| Atezolizumab | Breast | I/II | |
| Sodium phenylbutyrate (4-PBA) | Azacitidine | AML or myelodysplastic syndrome (MDS) | I |
| Tacedinaline (CI994) | Gemcitabine | Advanced NSCL | III |
| Gemcitabine | Advanced pancreatic | II | |
| Mocetinostat (MGCD0103) | Docetaxel | Advanced tumors | I |
| Brentuximab vedotin (SGN-35) | Relapsed/refractory Hodgkin lymphoma | I/II | |
| Azaxitidine | High-risk MDS or acute myelogenous leukemia | I/II | |
| Durvalumab | Squamous cell carcinoma or the oral cavity | I | |
| Abexinostat (PCI24781) | Doxorubicin | Soft tissue sarcoma | I/II |
| Pazopanib | Metastatic solid tumors | I | |
| Resminostat (4SC201) | Sorafenib | Hepatocellular carcinoma | I/II |
| Quisinostat (JNJ-26481585) | Paclitaxel and carboplatin | Ovarian | II |
| HBI-8000 | Nivolumab | Melanoma, renal cell carcinoma, and NSCLC | I/II |
| CUDC-101 | Cisplatin | Head and neck | I |
| AR42 | Decitabine | AML | I |
| Pomalidomide | Relapsed multiple myeloma | I | |
| 4SC202 | Pembrolizumab | Malignant melanoma | I/II |
| CG200745 | Gemcitabine and erlotinib | Advanced pancreatic | I/II |
| ME-344 | Toptecan | Solid tumors | I/II |
NIH clinical trial database: www.clinicaltrials.gov.